Advertisement

Abstract

This chapter summarizes the use of antidepressants and antimanic medications in children and adolescents. Antimanic medications that are also antiepileptics, such as carbamazepine, valproate, and clonazepam, are discussed here, but their pharmacological details are found in Chapter 12. The discussion on the use of antidepressants will focus on their use in mood disorders (for which they were originally introduced) and on their use in anxiety disorders, attention-deficit disorders, and enuresis.1–7 Since the first edition of this guide, more data concerning the use of selective or specific serotonin reuptake inhibitors (SSRIs) has become available, and treatment with more than one medication has become more common. This chapter will discuss the uses of SSRIs as well as combinations of medications in children and adolescents. Toxicity and treatment for toxicity will also be discussed.

Keywords

Anxiety Disorder Obsessive Compulsive Disorder Serotonin Syndrome Lithium Treatment Adolescent Depression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Quinn PO, Rapoport JL: One-year follow-up of hyperactive boys treated with imipramine or methylpheni-date. Am J Psychiatry 132:241–245, 1975.PubMedGoogle Scholar
  2. 2.
    Rapoport JL, Quinn PO, Bradbard G, et al: Imipramine and methylphenidate treatments of hyperactive boys: A double-blind comparison. Arch Gen Psychiatry 30:789–793, 1974.PubMedCrossRefGoogle Scholar
  3. 3.
    Werry JS, Aman MG, Diamond E: Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry 21:27–35, 1980.PubMedCrossRefGoogle Scholar
  4. 4.
    Pliszka SR: Antidepressants in the treatment of child and adolescent psychopathology. J Clin Child Psychol 20:313–320, 1991.CrossRefGoogle Scholar
  5. 5.
    Pliszka SR: Review article—Tricyclic antidepressants in the treatment of children with attention deficit disorder. J Am Acad Child Adolesc Psychiatry 26:127–132, 1987.PubMedCrossRefGoogle Scholar
  6. 6.
    Werry JS, Dowrick PW, Lampen EL, et al: Imipramine in enuresis—Psychological and physiological effects. J Child Psychol Psychiatry 16:289–299, 1975.PubMedCrossRefGoogle Scholar
  7. 7.
    Blackwell B, Curran J: The psychopharmacology of nocturnal enuresis, in Kolvin I, McKeith RC, Meadows SR (eds): Bladder Control and Enuresis. London, Heinemann, 1973, pp 231–257.Google Scholar
  8. 8.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association, 1994.Google Scholar
  9. 9.
    Kashani JH, Sherman DD: Childhood depression: Epidemiology, etiological models, and treatment implications. Integrative Psychiatry 6:1–21, 1988.Google Scholar
  10. 10.
    Ryan ND: Heterocyclic antidepressants in children and adolescents. J Child Adolesc Psychopharmacol 1: 21–31, 1990.PubMedCrossRefGoogle Scholar
  11. 11.
    Spencer T, Wilens T, Biederman J: Psychotropic medication for children and adolescents. Child Adolesc Clin North Am 4(1):97–121, 1995.Google Scholar
  12. 12.
    De Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry 57(suppl 4): 19–25, 1996.PubMedGoogle Scholar
  13. 13.
    American Hospital Formulary Service Drug Information. Bethesda, American Society of Hospital Pharmacists, 1991.Google Scholar
  14. 14.
    Baldessarini RJ: Current status of antidepressants: Clinical pharmacology and therapy. J Clin Psychiatry 50(4):117–126, 1989.PubMedGoogle Scholar
  15. 15.
    Physicians’ Desk Reference. Oradell, NJ, Medical Economics Data, 1997.Google Scholar
  16. 16.
    Baldessarini RJ, Cole JO: Chemotherapy, in Nicholi AM (ed): The New Harvard Guide to Psychiatry. Cambridge, Mass, Harvard University Press, 1988, pp 481–533.Google Scholar
  17. 17.
    Richelson E: Pharmacology of antidepressants—characteristics of the ideal drugs. Mayo Clin Proc 69:1069–1081, 1994.PubMedCrossRefGoogle Scholar
  18. 18.
    Morselli PL: Drug Disposition during Development. Jamaica, NY, Spectrum Publications, 1977.Google Scholar
  19. 19.
    Jatlow PI: Psychotropic drug disposition during development, in Popper C (ed): Psychiatric Pharmaco-science of Children and Adolescents. Washington, DC, American Psychiatric Press, 1989, pp 29–44.Google Scholar
  20. 20.
    Briant RH: An introduction to clinical pharmacology, in Werry JC (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978, pp 3–82.Google Scholar
  21. 21.
    De Vane CL, Jarecke CR: Cyclic antidepressants, in Evans WE, Schoentag J J, Jusko WJ (eds): Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. San Francisco, Applied Therapeutics, 1992, vol 33, pp 1–34.Google Scholar
  22. 22.
    Geller B, Cooper TB, Schluchter MD, et al: Child and adolescent nortriptyline single dose pharmacokinetic parameters: Final report. J Clin Psychopharmacol 7:321–323, 1987.PubMedGoogle Scholar
  23. 23.
    Moriselli PL, Bianchetti G, Dugas M: Therapeutic drug monitoring of psychotropic drugs in children. Pediatr Pharmacol 3:149–156, 1983.Google Scholar
  24. 24.
    deGatta MF, Garcia MJ, Acosta A, et al: Monitoring of serum levels of imipramine and desipramine and individuation of dose in enuretic children. Ther Drug Monit 6:438–443, 1984.CrossRefGoogle Scholar
  25. 25.
    Preskorn SH, Bupp SJ, Weller EB, et al: Plasma levels of imipramine and metabolites in 68 hospitalized children. J Am Acad Child Adolesc Psychiatry 28:373–375, 1989.PubMedCrossRefGoogle Scholar
  26. 26.
    Geller G, Cooper TB, Chestnut EC, et al: Preliminary data on the relationship between nortriptyline plasma level and response in depressed children. Am J Psychiatry 143:123–126, 1986.Google Scholar
  27. 27.
    Biederman J, Baldessarini RJ, Wright V, et al: A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777–784, 1989.PubMedCrossRefGoogle Scholar
  28. 28.
    Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T: Nortriptyline in the treatment of ADHD: A chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32:343–349, 1993.PubMedCrossRefGoogle Scholar
  29. 29.
    Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S: A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry 32:199–204, 1993.PubMedCrossRefGoogle Scholar
  30. 30.
    Gelenberg AJ, Schoonover SC: Depression, in Gelenberg AJ, Bassuk EL, Schoonover SC (eds): The Practitioner’s Guide to Psychoactive Drugs, ed 3. New York, Plenum Press, 1991, pp 23–89.CrossRefGoogle Scholar
  31. 31.
    Biederman J, Faraone SV, Baldessarini RJ, Flood J, Meyer M, Wilens T, Spencer T, Chen L, Weber W: Predicting desipramine levels in children and adolescents: A naturalistic clinical study. J Am Acad Child Adolesc Psychiatry 36:384–389, 1997.PubMedCrossRefGoogle Scholar
  32. 32.
    Oesterheld JR: Erythromycin and clomipramine: Noncompetitive inhibition of demethylation. J Child Adolesc Psychopharmacol 6:211–213, 1996.PubMedCrossRefGoogle Scholar
  33. 33.
    Bernstein JG: Handbook of Drug Therapy in Psychiatry, ed 2. Boston, PSG Publishing Co, 1988.Google Scholar
  34. 34.
    Hollister LE: Antidepressant drugs, in Dukes MNG (ed): Meyler’s Side Effects of Drugs, VIII. New York, American Elsevier Publishing, 1975, pp 31–46.Google Scholar
  35. 35.
    Klein DF, Gittleman R, Quitkin F, et al: Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children. Baltimore, Williams & Wilkins, 1980.Google Scholar
  36. 36.
    Klein RG, Koplewicz HS, Kanner A: Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 31:21–28, 1992.PubMedCrossRefGoogle Scholar
  37. 37.
    Gualtieri CT: Imipramine and children: A review and some speculations about the mechanism of drug action. Dis Nerv Syst 38:368–375, 1977.PubMedGoogle Scholar
  38. 38.
    Casat CD, Pleasants DZ, Schroeder DH, et al: Bupropion in children with attention deficit disorder. Psychopharmacol Bull 25:198–201, 1989.PubMedGoogle Scholar
  39. 39.
    Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Arndt SV, Herrmann KJ, Schumacher E: Bupropion vs methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:649–657, 1995.PubMedCrossRefGoogle Scholar
  40. 40.
    Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, Weller RA, Khayrallah M, Ascher J: Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314–1321, 1996.PubMedCrossRefGoogle Scholar
  41. 41.
    Aman MG: Psychotropic drugs and learning problems—a selective review. J Learn Disabil 13:87–97, 1980.PubMedCrossRefGoogle Scholar
  42. 42.
    Preskorn SH, Weller EB, Weller RA, et al: Plasma levels of imipramine and adverse effects in children. Am J Psychiatry 140:1332–1335, 1983.PubMedGoogle Scholar
  43. 43.
    Kuekes ED, Wigg C, Bryant S, Meyer WJ: Hypertension is a risk in adolescents treated with imipramine. J Child Adolesc Psychopharmacol 2:241–248, 1992.Google Scholar
  44. 44.
    Task Force on Blood Pressure Control in Children: Report of the second task force on blood pressure control in children. Pediatrics 79:1–25, 1987.Google Scholar
  45. 45.
    Riddle MA, Nelson JG, Kleinman CS, et al: Sudden death in children receiving Norpramin: A review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30:104–108, 1991.PubMedCrossRefGoogle Scholar
  46. 46.
    Biederman J: Sudden death in children treated with a tricyclic antidepressant. J Am Acad Child Adolesc Psychiatry 30:495–498, 1991.PubMedCrossRefGoogle Scholar
  47. 47.
    Riddle MA, Geller B, Ryan N: Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 32:792–797, 1993.PubMedCrossRefGoogle Scholar
  48. 48.
    Popper CW, Zimnitzky B: Sudden death putatively related to desipramine treatment in youth: A fifth case and a review of speculative mechanisms. J Child Adolesc Psychopharmacol 5:283–300, 1995.CrossRefGoogle Scholar
  49. 49.
    Varley CK, McClellan J: Case study: Two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 36:390–394, 1997.PubMedCrossRefGoogle Scholar
  50. 50.
    Saraf KR, Klein DF, Gittelman-Klein R, Groft S: Imipramine side effects in children. Psychopharmacologia 37(3):265–274, 1974.PubMedCrossRefGoogle Scholar
  51. 51.
    Wagner KD, Fershtman M: Potential mechanism of desipramine-related sudden death in children. Psycho-somatics 34:80–83, 1991.CrossRefGoogle Scholar
  52. 52.
    Leonard HL, Meyer MC, Swedo SE, Richter D, Hamburger SD, Allen AJ, Rapoport JL, Tucker E: Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry 34:1460–1468, 1995.PubMedCrossRefGoogle Scholar
  53. 53.
    Fletcher SE, Case CL, Sallee FR, Hand LD, Gillette PC: Prospective study of the electrocardiographic effects of imipramine in children. J Pediatr 122:654–654, 1993.Google Scholar
  54. 54.
    Jackson WK, Roose SP, Glassman AH: Cardiovascular toxicity of antidepressant medications. Psycho-pathology 20:64–71, 1987.CrossRefGoogle Scholar
  55. 55.
    Elliott GR, Popper GW: Tricyclic antidepressants: The QT interval and other cardiovascular parameters. J Child Adolesc Psychopharmacol 1:187–189, 1990/1991.CrossRefGoogle Scholar
  56. 56.
    Alderton HR: Tricyclic medication in children and the QT interval: Case report and discussion. Can J Psychiatry 40:325–329, 1995.PubMedGoogle Scholar
  57. 57.
    Blackwell B: Adverse effects of antidepressant drugs. Part I: Monoamine oxidase inhibitors and tricyclics. Drugs 21:201–219, 1981.PubMedCrossRefGoogle Scholar
  58. 58.
    Sovner R, DiMascio A: Extrapyramidal syndromes and other neurological side effects of psychotropic drugs, in Lipton MA, DiMascio A, Killam DF (eds): Psychopharmacology: A Generative of Progress. New York, Raven Press, 1978, pp 1021–1032.Google Scholar
  59. 59.
    Petti TA, Law W: Abrupt cessation of high-dose imipramine treatment in children. JAMA 246:768–769, 1981.PubMedCrossRefGoogle Scholar
  60. 60.
    Viesselman JO, Weller EB, Weller RA, Yaylayan S: Current psychopharmacologic treatment research of depressed children and adolescents, in Sholevar GP (ed): The Transmission of Depression in Families and Children: Assessment and Intervention. Northvale, NJ, Jason Aronson Inc., 1994.Google Scholar
  61. 61.
    Preskorn SH, Weiler EB, Hughes CW, et al: Depression in prepubertal children: Dexamethasone non-suppression predicts differential response to imipramine vs placebo. Psychopharmacol Bull 23:128–133, 1987.PubMedGoogle Scholar
  62. 62.
    Puig-Antich J, Perel JM, Lupatkin W, et al: Imipramine in prepubertal major depressive disorder. Arch Gen Psychiatry 44:81–89, 1987.PubMedCrossRefGoogle Scholar
  63. 63.
    Geller B, Cooper TB, Graham DL, et al: Pharmacokinetically-designed double-blind, placebo-controlled study of nortriptyline in 6–12 year olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 31:34–44, 1992.PubMedCrossRefGoogle Scholar
  64. 64.
    Puig-Antich J, Perel JM, Lupatkin W, et al: Plasma levels of imipramine (IMI) and desmethylimipramine (DMI), and clinical response in prepubertal major depressive disorder. A preliminary report. J Am Acad Child Psychiatry 18:616–627, 1979.PubMedCrossRefGoogle Scholar
  65. 65.
    Petti TH, Conners CK: Changes in behavioral ratings of depressed children treated with imipramine. J Am Acad Child Adolesc Psychiatry 22:355–360, 1983.CrossRefGoogle Scholar
  66. 66.
    Kashani JH, Shekim WO, Reid JC: Amitriptyline in children with major depressive disorder: A double-blind crossover pilot study. J Am Acad Child Psychiatry 23:348–351, 1984.PubMedCrossRefGoogle Scholar
  67. 67.
    Hazell P, O’Connell D, Heathcote D, Robertson J, Henry D: Efficacy of tricyclic drugs in treating child and adolescent depressions: A meta-analysis. Br Med J 310:897–901, 1995.CrossRefGoogle Scholar
  68. 68.
    Kramer A, Feiguine R: Clinical effects of amitriptyline in adolescent depression. J Am Acad Child Psychiatry 33:686–644, 1981.Google Scholar
  69. 69.
    Geller B, Cooper TB, Graham DL, et al: Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a “fixed plasma level” design. Psychopharmacol Bull 26:85–90, 1990.PubMedGoogle Scholar
  70. 70.
    Ryan ND, Puig-Antich J, Cooper T, et al: Imipramine in adolescent major depression: Plasma level and clinical response. Acta Psychiatr Scand 73:275–288, 1986.PubMedCrossRefGoogle Scholar
  71. 71.
    Kye CH, Waterman CS, Ryan ND, Birmaher B, Williamson DE, Iyencar S, Dachille S: A randomized controlled trial of amitriptyline in the acute treatment of adolescent major depression. J Am Acad Child Adolesc Psychiatry 35:1139–1144, 1996.PubMedCrossRefGoogle Scholar
  72. 72.
    Boulos C, Kutcher S, Marton P, Simeon J, Ferguson B, Roberts N: Response to desipramine treatment in adolescent major depression. Psychopharmacol Bull 27:59–65, 1991.PubMedGoogle Scholar
  73. 73.
    Robbins DR, Alessi NE, Colfer MV: Treatment of adolescents with major depression: Implications of the DST and the melancholic clinical subtype. J Affect Disord 17:99–104, 1989.PubMedCrossRefGoogle Scholar
  74. 74.
    Strober M, Freeman R, Rigali J: The pharmacotherapy of depressive illness in adolescence, I: An open label trial of imipramine. Psychopharmacol Bull 26:80–84, 1990.PubMedGoogle Scholar
  75. 75.
    Ambrosini PJ, Bianchi MD, Metz C, Rabinovich H: Evaluating clinical response of open nortriptyline pharmacotherapy in adolescent major depression. J Child Adolesc Psychopharmacol 4:233–244, 1994.CrossRefGoogle Scholar
  76. 76.
    Green WH: The treatment of Attention Deficit Hyperactivity Disorder with nonstimulant medications. Child Adolesc Clin North Am 4(1):169–195, 1995.Google Scholar
  77. 77.
    Psychotropics & seizure. Just the Fax 2(3):5, 1995.Google Scholar
  78. 78.
    Kaplan SL, Breit M, Gauthier B, et al. A comparison of three nocturnal enuresis treatment methods. J Am Acad Child Adolesc Psychiatry 28:282–286, 1989.PubMedCrossRefGoogle Scholar
  79. 79.
    Berney T, Kolvin I, Bhate SR, et al: School phobia: A therapeutic trial with clomipramine and short-term outcome. Br J Psychiatry 138:110–118, 1981.PubMedCrossRefGoogle Scholar
  80. 80.
    Bernstein GA, Garfinkel BD, Borchardt DM: Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry 29:773–781, 1990.PubMedCrossRefGoogle Scholar
  81. 81.
    Klein RG, Koplewicz HS, Kanner A: Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 31:21–28, 1992.PubMedCrossRefGoogle Scholar
  82. 82.
    Rament MF, Rapoport JL, Berg CJ, et al: Clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 42:977–983, 1985.CrossRefGoogle Scholar
  83. 83.
    Leonard HL, Swedo SE, Rapoport JL, et al: Treatment of obsessive-compulsive disorder in children and adolescents: A double-blind crossover comparison. Arch Gen Psychiatry 46:1088–1092, 1989.PubMedCrossRefGoogle Scholar
  84. 84.
    DeVeaugh-Geiss J, Moroz G, Biederman J, Cantwell, D, Fontaine R, Greist JH, Reichler R, Katz R, Landau P: Clomipramine in child and adolescent obsessive-compulsive disorder—A multicenter trial. J Am Acad Child Adolesc Psychiatry 31:45–49, 1992.PubMedCrossRefGoogle Scholar
  85. 85.
    Hanna GL, Yuwiler A, Cantwell DP: Whole-blood serotonin during clomipramine treatment of juvenile obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 3:223–229, 1993.CrossRefGoogle Scholar
  86. 86.
    Swedo SE, Leonard HL, Rapoport JL, et al: A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 321:497–501, 1989.PubMedCrossRefGoogle Scholar
  87. 87.
    Riley WT, Sood A, Al-Mateen CS: Mixed effects of clomipramine in treating childhood trichotillomania. J Child Adolesc Psychopharmacol 3:169–171, 1993.PubMedCrossRefGoogle Scholar
  88. 88.
    Weiler EB, Weller RA, Carr S: Case study—imipramine treatment of trichotillomania and coexisting depression in a seven-year-old. J Am Acad Child Adolesc Psychiatry 28:952–953, 1989.CrossRefGoogle Scholar
  89. 89.
    Sheikha SH, Wagner KD, Wagner RF: Fluoxetine treatment of trichotillomania and depression in a prepubertal child. Cutis 51(l):50–52, 1993.PubMedGoogle Scholar
  90. 90.
    Zubieta JK, Alessi NE: Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children. J Clin Psychopharmacol 12:346–351, 1992.PubMedGoogle Scholar
  91. 91.
    Ghaziuddin N, Alessi NE: An open clinical trial of trazodone in aggressive children. J Child Adolesc Psychopharmacol 2:291–297, 1992.PubMedCrossRefGoogle Scholar
  92. 92.
    Garber HJ, McGonigle JJ, Slomka GT, Monteverde E: Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry 31:1157–1160, 1992.PubMedCrossRefGoogle Scholar
  93. 93.
    Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL: A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441–447, 1993.PubMedCrossRefGoogle Scholar
  94. 94.
    Lewis MH, Bodfish JW, Powell SB, Parker DE, Golden RN: Clomipramine treatment for self-injurious behavior of individuals with mental retardation: A double-blind comparison with placebo. Am J Ment Retard 100:654–665, 1996.PubMedGoogle Scholar
  95. 95.
    McDougle CJ, Price LH, Volkmar FR, et al: Clomipramine in autism: Preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry 31:746–750, 1992.PubMedCrossRefGoogle Scholar
  96. 96.
    Ponto LB, Perry PJ, Liskow BI, et al: Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am J Hosp Pharm 34:954–961, 1977.PubMedGoogle Scholar
  97. 97.
    Briant RH, Reid JL, Dollery CT: Interaction between Clonidine and desipramine in man. Br Med J 1:522 – 523, 1973.PubMedCrossRefGoogle Scholar
  98. 98.
    Mitchel L Jr, Arias L, Oates JA: Antagonism of hypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA 202:973–976, 1967.CrossRefGoogle Scholar
  99. 99.
    Perucca E, Richens A: Interactions between phenytoin and imipramine. Br J Clin Pharmacol 4:485–486, 1977.PubMedCrossRefGoogle Scholar
  100. 100.
    Ballinger BR, Presly A, Reid AH: The effects of hypnotics on imipramine treatment. Psychopharmacologia 39:267–274, 1974.PubMedCrossRefGoogle Scholar
  101. 101.
    Wharton RN, Perel JM, Dayton PG, et al: A potential clinical use of methylphenidate with tricyclic antidepressants. Am J Psychiatry 127:1619–1625, 1971.PubMedGoogle Scholar
  102. 102.
    Langou RA, Van Dyke C, Tahan SR, et al: Cardiovascular manifestations of tricyclic antidepressant overdose. Am Heart J 100:458–464, 1980.PubMedCrossRefGoogle Scholar
  103. 103.
    Dumovic P, Burrows G, Vohra J, et al: The effect of tricyclic antidepressant drugs on the heart. Arch Toxicol 35:255–262, 1976.PubMedCrossRefGoogle Scholar
  104. 104.
    Frommer DA, Kulig KW, Marx JA, Rumack B: Tricyclic antidepressant overdose: A review. JAMA 257: 521–526, 1987.PubMedCrossRefGoogle Scholar
  105. 105.
    Barone MA (ed): The Harriet Lane Handbook. A Manual for Pediatric House Officers, ed 14. St Louis, Mosby, 1996.Google Scholar
  106. 106.
    Rumack BH: Poisondex, Rocky Mountain Poison Center, Denver, 1982.Google Scholar
  107. 107.
    Pumariega AJ, Muller B, Rivers-Bulkeley N: Acute renal failure secondary to amoxapine overdose. JAMA 248:3141–3142, 1982.PubMedCrossRefGoogle Scholar
  108. 108.
    Puig-Antich J, Ryan ND, Rabinovich H: Affective disorders in childhood and adolescence, in Weiner J (ed): Diagnosis and Psychopharmacology of Childhood and Adolescent Disorders. New York, John Wiley & Sons, 1985.Google Scholar
  109. 109.
    Rudorfer MV: Monoamine oxidase inhibitors: Reversible and irreversible. Psychopharmacol Bull 28:45–57, 1992.PubMedGoogle Scholar
  110. 110.
    Baldessarini RJ: Drugs and the treatment of psychiatric disorders, in Gilman AG, Rall TW, Nies AS, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 418–422.Google Scholar
  111. 111.
    Green WH. Child and Adolescent Clinical Psychopharmacology. Baltimore, Williams & Wilkins, 1991, pp 134–137.Google Scholar
  112. 112.
    Akiskal HS: Mood disturbances, in Winokur G, Clayton P (eds): The Medical Basis of Psychiatry. Philadelphia, WB Saunders Co, 1986.Google Scholar
  113. 113.
    Fitton A, Faulds D, Goa KL: Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43:561–596, 1992.PubMedCrossRefGoogle Scholar
  114. 114.
    Ryan N, Puig-Antich J, Rabinovich H, et al: MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 27:755–758, 1988.PubMedCrossRefGoogle Scholar
  115. 115.
    Zametkin AJ, Rapoport JL: Noradrenergic hypothesis of attention deficit disorder with hyperactivity: A critical review, in Meltzer HY (ed): Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987.Google Scholar
  116. 116.
    Zametkin A, Rapoport JL, Murphy DL, et al: Treatment of hyperactive children with monoamine oxidase inhibitors: I. Clinical efficacy. Arch Gen Psychiatry 42:962–966, 1985.PubMedCrossRefGoogle Scholar
  117. 117.
    Trott GE, Friese HJ, Menzel M, Nissen G: Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology (Supplement) 106:134–136, 1992.CrossRefGoogle Scholar
  118. 118.
    Sternbach H: The serotonin syndrome. Am J Psychiatry 148:705–713, 1991.PubMedGoogle Scholar
  119. 119.
    Turner P, Young JH, Paterson J: Influence of urinary pH on the excretion of tranylcypromine sulfate. Nature 215:881–882, 1967.PubMedCrossRefGoogle Scholar
  120. 120.
    Matter BJ, Donat PE, Bril ML, et al: Tranylcypromine sulfate poisoning: Successful treatment with hemodialysis. Arch Intern Med 116:18–20, 1965.PubMedCrossRefGoogle Scholar
  121. 121.
    Versaci AA, Nakamoto S, Koloff WJ: Phenelzine intoxication: Report of a case treated by hemodialysis. Ohio State Med J 60:770–771, 1964.PubMedGoogle Scholar
  122. 122.
    Sussman N: The potential benefits of serotonin receptor-specific agents. J Clin Psychiatry 55 [2(suppl)]: 45–51, 1994.PubMedGoogle Scholar
  123. 123.
    Brown TM, Skop BP, Mareth TR: Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 30:527–533, 1996.PubMedGoogle Scholar
  124. 124.
    Grimsley SR, Jann MW: Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clin Pharm 11:930–957, 1992.PubMedGoogle Scholar
  125. 125.
    Loenard HL, March J, Rickler KC, Allen AJ: Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry 36:725–736, 1997.CrossRefGoogle Scholar
  126. 126.
    Clein PD, Riddle MA: Pharmacokinetics in children and adolescents. Child Adolesc Clin North Am 4(1): 59–75, 1995.Google Scholar
  127. 127.
    Riesenman C: Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal. Pharmacotherapy 15(6 Pt 2):845–995, 1995.Google Scholar
  128. 128.
    Nemeroff CB, DeVane L, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311–320, 1996.PubMedGoogle Scholar
  129. 129.
    Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N: Fluoxetine in children and adolescents with mood disorders: A chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacol 2:259–265, 1992.PubMedCrossRefGoogle Scholar
  130. 130.
    Boulos C, Kutcher S, Gardner D, Young E: An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression. J Child Adolesc Psychopharmacol 2:103–111, 1992.PubMedCrossRefGoogle Scholar
  131. 131.
    Ghaziuddin N, Naylor MW, King CA: Fluoxetine in tricyclic refractory depression in adolescents. Depression 2:287–291, 1995.CrossRefGoogle Scholar
  132. 132.
    Tierney E, Paramjit JT, Leinas JF, Rosenberg LA, Riddle MA: Sertraline for major depression in children and adolescents: Preliminary Clinical experience. J Child Adolesc Psychopharmacol 5:13–27, 1995.CrossRefGoogle Scholar
  133. 133.
    Colle LM, Belair J, DiFeo M, Weiss J, LaRoche C: Extended open-label fluoxetine treatment of adolescents with major depression. J Child Adolesc Psychopharmacol 4:225–232, 1994.CrossRefGoogle Scholar
  134. 134.
    Sallee FR, Nesbitt L, Dougherty D, Hilal R, Nandagopal VS, Sethuraman G: Lymphocyte glucocorticoid receptor: Predictor of sertraline response in adolescent major depressive disorder (MDD). Psychopharmacol Bull 31:339–345, 1995.PubMedGoogle Scholar
  135. 135.
    McConville BJ, Minnery KL, Sorter MT, West SA, Friedman LM, Christian K: An open study of the effects of sertraline on adolescent major depression. J Child Adolesc Psychopharmacol 6:41–51, 1996.PubMedCrossRefGoogle Scholar
  136. 136.
    Simeon J, Dinicola V, Ferguson HB, Copping W: Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up. Prog Neuro-psychopharmacol Biol Psychiatry 14:791–795, 1990.CrossRefGoogle Scholar
  137. 137.
    Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry, 54:1031–1037, 1997.PubMedCrossRefGoogle Scholar
  138. 138.
    Kye C, Ryan N: Pharmacologic treatment of child and adolescent depression. Child Adolesc Clin North Am 4(1):261–281, 1995.Google Scholar
  139. 139.
    Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M: Treatment of ADHD with fluoxetine: A preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762–767, 1991.PubMedGoogle Scholar
  140. 140.
    Bradley SJ, Kulik L: Fluoxetine and memory impairment. J Am Acad Child Adolesc Psychiatry 32:1078–1079,1993.PubMedCrossRefGoogle Scholar
  141. 141.
    Bangs ME, Petti TA, Janus MD: Ruoxetine-induced memory impairment in an adolescent. J Am Acad Child Adolesc Psychiatry 33:1303–1308, 1994.PubMedCrossRefGoogle Scholar
  142. 142.
    Hedges D, Reimherr FW, Rogers A, Strong R, Wender PH: An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 31:779–783, 1995.PubMedGoogle Scholar
  143. 143.
    Olvera RL, Pliszka SR, Luh J, Tatum R: An open trial of venlafaxine in the treatment of attention-deficit/ hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 6:241–250, 1996.PubMedCrossRefGoogle Scholar
  144. 144.
    Manassis K, Bradley S: Fluoxetine in anxiety disorders [letter]. J Am Acad Child Adolesc Psychiatry 33:761–762, 1994.PubMedCrossRefGoogle Scholar
  145. 145.
    Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, Brodsky M: Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33:993–999, 1994.PubMedCrossRefGoogle Scholar
  146. 146.
    Dummitt ES, Tancer NK, Klein RG: An open trial of fluoxetine for children with elective mutism. Psychopharmacol Bull 30:667, 1994.Google Scholar
  147. 147.
    Geller DA, Biederman J, Reed ED, Spencer T, Wilens TE: Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 34:36–44, 1995.PubMedCrossRefGoogle Scholar
  148. 148.
    Riddle MA, Hardin MT, King R, Scahill L, Woolston JL: Fluoxetine treatment of children and adolescents with Tourette’s and obsessive compulsive disorders: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29:45–48, 1990.PubMedCrossRefGoogle Scholar
  149. 149.
    Apter A, Ratzioni G, King R: Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 33:342–348, 1994.PubMedCrossRefGoogle Scholar
  150. 150.
    Fairbanks JM, Pine DS, Tancer NK, Dummit ES, Kentgen LM, Martin J, Asche BK, Klein RG: Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol 7:17–29, 1997.PubMedCrossRefGoogle Scholar
  151. 151.
    Dummit ES, Klein RG, Tancer NK, Asche B, Martin J: Fluoxetine treatment of children with selective mutism: An open trial. J Am Acad Child Adolesc Psychiatry 35:615–621, 1996.PubMedCrossRefGoogle Scholar
  152. 152.
    Kurlan R, Como PG, Deeley C, McDermott M, McDermott MP: A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette’s syndrome. Clin Neuropharmacol 16:167–172, 1993.PubMedCrossRefGoogle Scholar
  153. 153.
    Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckman JF, Cohen DJ: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31:1062–1069, 1992.PubMedCrossRefGoogle Scholar
  154. 154.
    Black B, Uhde TW: Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 33:1000–1006, 1994.PubMedCrossRefGoogle Scholar
  155. 155.
    Cook EH, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 31:739–745, 1992.PubMedCrossRefGoogle Scholar
  156. 156.
    Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP: Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 7:9–15, 1997.PubMedCrossRefGoogle Scholar
  157. 157.
    Preskorn SH, Janicak PG, Davis JM, Ayd FJ: Advances in the pharmacotherapy of depressive disorders. Principles and Practices of Psychopharmacotherapy, Williams & Wilkins, Baltimore, 1(2):1–24, 1995.Google Scholar
  158. 158.
    Brody JF: Bait poisoning and why kids complain about their medication. J Child Adolesc Psychopharmacol 7:71–72, 1997.PubMedCrossRefGoogle Scholar
  159. 159.
    Venkataraman S, Naylor MW, King CA: Mania associated with fluoxetine treatment in adolescents. J Am Acad Child Adolesc Psychiatry 31:276–281, 1992.PubMedCrossRefGoogle Scholar
  160. 160.
    Riddle MA, King RA, Hardin MT, Scahill L, et al: Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1:193–198, 1990.CrossRefGoogle Scholar
  161. 161.
    Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J: Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. J Clin Psychiatry 58(suppl 7):5–10, 1997.PubMedGoogle Scholar
  162. 162.
    Lejoyeux M, Ades J: Antidepressant discontinuation: A review of the literature. J Clin Psychiatry 58(suppl 7):11–16, 1997.PubMedGoogle Scholar
  163. 163.
    Rosenbaum JF, Zajecka J: Clinical management of antidepressant discontinuation. J Clin Psychiatry 58(suppl 7):37–40, 1997.PubMedGoogle Scholar
  164. 164.
    Parraga HC, Kelly DP, Parraga MI, Cochran M, Maxim LT: Combined psychostimulant and tricyclic antidepressant treatment of Tourette’s syndrome and comorbid disorders in children. J Child Adolesc Psychopharmacol 4:113–122, 1994.CrossRefGoogle Scholar
  165. 165.
    Carlson GA, Rapport MD, Kelly KL, Pataki CS: Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: Separate and combined effects on behavior and mood. J Child Adolesc Psychopharmacol 5:191–204, 1995.CrossRefGoogle Scholar
  166. 166.
    Simeon JG, Thatte S, Wiggins D: Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 26:285–290, 1990.PubMedGoogle Scholar
  167. 167.
    Findling RL: Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: A case series. J Child Adolesc Psychopharmacol 6:165–175, 1996.PubMedCrossRefGoogle Scholar
  168. 168.
    Gammon GD, Brown TE: Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 3:1–10, 1993.PubMedCrossRefGoogle Scholar
  169. 169.
    Brown WA, Harrison W: Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 28:253–256, 1992.PubMedGoogle Scholar
  170. 170.
    Weiler EB, Weller RA, Svadjian H: Mood Disorders, in Lewis M (ed): Child and Adolescent Psychiatry: A Comprehensive Textbook. Baltimore, Williams & Wilkins, 1996, pp 650–665.Google Scholar
  171. 171.
    Varanka TM, Weller RA, Weller EB, et al: Lithium treatment of manic episodes with psychotic features in prepubertal children. Am J Psychiatry 145:1557–1559, 1988.PubMedGoogle Scholar
  172. 172.
    Weller RA, Weller EB, Tucker SG, et al: Mania in prepubertal children: Has it been underdiagnosed? J Affect Disord 11:151–154, 1986.PubMedCrossRefGoogle Scholar
  173. 173.
    Goodwin FK, Jamison KR: Manic-Depressive Illness. New York, Oxford University Press, 1990.Google Scholar
  174. 174.
    Robins LN, Heizer JR, Weissman MM, et al.: Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949–958, 1984.PubMedCrossRefGoogle Scholar
  175. 175.
    Cade JF: Lithium salts in the treatment of psychotic excitement. Med J Aust 11:349–352, 1949.Google Scholar
  176. 176.
    Prien RF, Caffey EM, Klett CJ: Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 28:337–341, 1973.PubMedCrossRefGoogle Scholar
  177. 177.
    Rapoport JL, Mikkelsen EJ, Werry JS: Antimanic, antianxiety, hallucinogenic and miscellaneous drugs, in Werry JS (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978, pp 316–355.Google Scholar
  178. 178.
    Jefferson JW: The use of lithium in childhood and adolescence: An overview. J Clin Psychiatry 43:174–177, 1982.PubMedGoogle Scholar
  179. 179.
    Schou M: Lithium in psychiatric therapy and prophylaxis. J Psychiatr Res 6:67–95, 1971.CrossRefGoogle Scholar
  180. 180.
    Jefferson JW, Greist JH, Ackerman DL, et al: Mechanism of action, in Jefferson JW, Greist JH, Ackerman DL, et al (eds): Lithium Encyclopedia for Clinical Practice, ed 2. Washington, DC, American Psychiatric Press, 1987, pp 436–441.Google Scholar
  181. 181.
    Carlson GA: Bipolar disorders in children and adolescents, in Garfinkel B, Carlson G, Weller E (eds): Psychiatric Disorders in Children and Adolescents. Philadelphia, WB Saunders Co, 1990, pp 21–36.Google Scholar
  182. 182.
    Amdisen A, Carson S: Lithium, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Spokane, Wash, Applied Therapeutics, 1986, pp 97–100.Google Scholar
  183. 183.
    Perry PJ, Alexander B, Liskow BI: Antimanic agents, in Perry PJ, Alexander B, Liskow BI (eds): Psychotropic Drug Handbook, ed 5. Concinnati, Harvey Whitney Books, 1988, pp 85–112.Google Scholar
  184. 184.
    Appleton WS: Pharmacological treatment for affective disorders, in Appleton WS (ed): Practical Clinical Psychopharmacology, ed 3. Baltimore, Williams & Wilkins, 1988, pp 81–150.Google Scholar
  185. 185.
    Fetner HH, Geller B: Lithium and tricyclic antidepressants. Psychiatr Clin North Am 15:223–241, 1992.PubMedGoogle Scholar
  186. 186.
    Platt JE, Campbell M, Green WH, et al: Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Arch Gen Psychiatry 41:657–662, 1984.PubMedCrossRefGoogle Scholar
  187. 187.
    Campbell M, Schulman D, Rapoport J: The current status of lithium therapy in child and adolescent psychiatry. J Am Acad Child Psychiatry 14:717–729, 1978.Google Scholar
  188. 188.
    Campbell M, Cohen IL, Small AM: Drugs in aggressive behavior. J Am Acad Child Psychiatry 21:107–117, 1982.PubMedCrossRefGoogle Scholar
  189. 189.
    Campbell M, Fish B, Korein J, et al: Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children. J Autism Child Schizophrenia 2:234–263, 1972.CrossRefGoogle Scholar
  190. 190.
    Gram LF, Rafaelson OJ: Lithium treatment of psychotic children and adolescents. Acta Psychiatr Scand 48:253–260, 1972.PubMedCrossRefGoogle Scholar
  191. 191.
    Hagino OR, Weiler EB, Weller RA, Washing D, Fristad MA, Kontras SB: Untoward effects of lithium treatment in children aged four through six years. J Am Acad Child Adolesc Psychiatry 34:1584–1590, 1995.PubMedCrossRefGoogle Scholar
  192. 192.
    Carlson GA, Rapport MD, Kelly KL, et al: The effect of methylphenidate and lithium on attention and activity level. J Am Acad Child Adolesc Psychiatry 31:262–270, 1992.PubMedCrossRefGoogle Scholar
  193. 193.
    Campbell M, Silva RR, Kafantaris V, Locascio J J, Gonzalez NM, Lee D, Lynch NS: Predictors of side effects associated with lithium administration in children. Psychopharmacol Bull 27:373–380, 1991.PubMedGoogle Scholar
  194. 194.
    Silva RR, Campbell M, Golden RR, Small AM, Pataki CS, Rosenberg CR: Side effects associated with lithium and placebo administration in aggressive children. Psychopharmacol Bull 28:319–326, 1992.PubMedGoogle Scholar
  195. 195.
    Campbell M, Small AM, Green WH, et al: Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650–656, 1984.PubMedCrossRefGoogle Scholar
  196. 196.
    Campbell M, Green WH, Deutsch SI: Child and Adolescent Psychopharmacology. Beverly Hills, Sage Publications, 1985.Google Scholar
  197. 197.
    Deandrea D, Walker N, Nehlmauer M, et al: Dermatological reactions to lithium: A critical review of the literature. J. Clin Psychopharmacol 2:199–204, 1982.PubMedCrossRefGoogle Scholar
  198. 198.
    Jefferson JW: Lithium and tetracycline. Br J Dermatol 107:370, 1982.CrossRefGoogle Scholar
  199. 199.
    Herskowitz J: Developmental toxicology, in Popper C (ed): Psychiatric Pharmacosciences of Children and Adolescents. Washington, DC, American Psychiatric Press, 1987.Google Scholar
  200. 200.
    Birch NJ, Horsman A, Hullin RP: Lithium, bone and body weight studies in long-term treated patients and in the rat. Neuropsychobiology 8(2):82–92, 1982.Google Scholar
  201. 201.
    Wilson WH, Jefferson JW: Thyroid disease, behavior and psychopharmacology. Psychosomatics 26:481–492, 1985.PubMedCrossRefGoogle Scholar
  202. 202.
    Vendborg PB, Bech P, Rafaelsen OJ: Lithium treatment and weight gain. Acta Psychiatr Scand 53:139–147, 1976.CrossRefGoogle Scholar
  203. 203.
    Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment: A survey of 237 patients in long-term treatment. Acta Psychiatr Scand 62:193–200, 1980.PubMedCrossRefGoogle Scholar
  204. 204.
    Kirk L, Baastrup PC, Schou M: Propranolol treatment of lithium-induced tremor. Lancet 2:106–107, 1973.Google Scholar
  205. 205.
    Reisberg B, Gershon S: Side effects associated with lithium therapy. Arch Gen Psychiatry 36:879–887, 1979.PubMedCrossRefGoogle Scholar
  206. 206.
    Joffe RT, Kellner CG, Post RM, et al: Lithium increases in platelet count [letter]. N Engl J Med 311:674–675, 1984.PubMedGoogle Scholar
  207. 207.
    Wood IK, Parmelee DX, Foreman JW: Lithium-induced nephrotic syndrome. Am J Psychiatry 146:84–87, 1989.PubMedGoogle Scholar
  208. 208.
    Khandelwal SK, Varma CK, Marthy RS: Renal function in children receiving long-term lithium prophylaxis. Am J Psychiatry 141:278–279, 1984.PubMedGoogle Scholar
  209. 209.
    Suppes T, Baldessarini RJ, Faedda GL, Tohen M: Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 48:1082–1088, 1991.PubMedCrossRefGoogle Scholar
  210. 210.
    Goodwin GM: Recurrence of mania after lithium withdrawal. Br J Psychiatry 164:149–152, 1994.PubMedCrossRefGoogle Scholar
  211. 211.
    Alessi N, Naylor MW, Ghaziuddin M, Zubieta JK: Update on lithium carbonate therapy in children and adolescents, J Am Acad Child Adolesc Psychiatry 33:291–304, 1994.PubMedCrossRefGoogle Scholar
  212. 212.
    Delong R, Aldershof AL: Long-term experience with lithium treatment in childhood: Correlation with clinical diagnosis. J Am Acad Child Adolesc Psychiatry 26:389–394, 1987.PubMedCrossRefGoogle Scholar
  213. 213.
    Youngerman J, Canino IA: Lithium carbonate use in children and adolescents: A survey of the literature. Arch Gen Psychiatry 35:216–224, 1978.PubMedCrossRefGoogle Scholar
  214. 214.
    Lena B: Lithium treatment of children and adolescents, in Johnson FN (eds): Handbook of Lithium Therapy. Lancaster, Penn, MTP Press, 1980, pp 405–413.CrossRefGoogle Scholar
  215. 215.
    Strober M, Morrel W, Lampert C, et al: Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness. A naturalistic study. Am J Psychiatry 147:457–461, 1990.PubMedGoogle Scholar
  216. 216.
    Carlson GA, Kashani JH: Manic symptoms in a non-referred adolescent population. J Affect Disord 15: 219–226, 1988.PubMedCrossRefGoogle Scholar
  217. 217.
    Werry JS, McClellan JM, Chard L: Childhood and adolescent schizophrenic, bipolar and schizoaffective disorders. A clinical and outcome study. J Am Acad Child Adolesc Psychiatry 30:457–465, 1991.PubMedCrossRefGoogle Scholar
  218. 218.
    Strober M, Carlson GA: Bipolar illness in adolescents with major depression: Clinical, genetic, and psycho-pharmacologic predictors in a 3 to 4-year prospective follow up investigation. Arch Gen Psychiatry 39:549–555, 1982.PubMedCrossRefGoogle Scholar
  219. 219.
    Akiskal HS, Down SJ, Jordan P, et al: Affective disorders in referred children and younger siblings and manic depressives. Arch Gen Psychiatry 42:996–1004, 1985.PubMedCrossRefGoogle Scholar
  220. 220.
    Stewart MA, Beblois CS, Meardon J, et al: Aggressive conduct disorder of children: The clinical picture. J Nerv Ment Dis 16:604–610, 1980.CrossRefGoogle Scholar
  221. 221.
    Campbell M: Psychopharmacology, in Noshpitz JD (ed): Basic Handbook of Child Psychiatry. New York, Basic Books, 1979, vol 3, pp 376–409.Google Scholar
  222. 222.
    Campbell M, Adams PB, Small AM, Kafantaris V, Silva RR, Shell J, Perry R, Overall JE: Lithium in hospitalized aggressive children with conduct disorder: A double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 34:445–453, 1995.PubMedCrossRefGoogle Scholar
  223. 223.
    Rifkin A, Karajgi B, Dicker R, Perl E, Boppana V, Hasan N, Pollack S: Lithium treatment of conduct disorders in adolescents. Am J Psychiatry 154:554–555, 1997.PubMedGoogle Scholar
  224. 224.
    Licamele WL, Goldberg RL: The concurrent use of lithium and methylphenidate in a child. J Am Acad Child Adolesc Psychiatry 28:785–787, 1989.PubMedCrossRefGoogle Scholar
  225. 225.
    Ryan N, Meyer VA, Dachille S, et al: Lithium antidepressant augmentation in TCA-refractory depression in adolescents. J Am Acad Child Adolesc Psychiatry 27:371–376, 1988.PubMedCrossRefGoogle Scholar
  226. 226.
    Strober M, Freeman R, Rigali J, et al: The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine. J Am Acad Child Adolesc Psychiatry 31:16–20, 1992.PubMedCrossRefGoogle Scholar
  227. 227.
    Weiler EB, Weller RA, Fristad MA: Lithium dosage guide for prepubertal children: A preliminary report. J Am Acad Child Adolesc Psychiatry 25:92–95, 1986.CrossRefGoogle Scholar
  228. 228.
    Campbell M, Small AM, Green WM, et al: Lithium and haloperidol in hospitalized aggressive children. Psychopharmacol Bull 1:125–130, 1982.Google Scholar
  229. 229.
    Siassi I: Lithium treatment of impulsive behavior in children. J Clin Psychiatry 43:42–44, 1982.Google Scholar
  230. 230.
    Persson G: Lithium side effects in relation to dose and to levels of lithium in plasma. Acta Psychiatr Scand 51:285–288, 1975.Google Scholar
  231. 231.
    Jefferson JW: Treating affective disorders in the presence of cardiovascular disease. Psychiatr Clin North Am 6:141–155, 1983.PubMedGoogle Scholar
  232. 232.
    Lippmann S, Wagemaker H, Tucker D: A practical approach to management of lithium concurrent with hyponatremia, diuretic therapy and/or chronic renal failure. J Clin Psychiatry 42:304–306, 1981.PubMedGoogle Scholar
  233. 233.
    Tyrer SP: Lithium in the treatment of mania. J Affect Disord 8:251–257, 1985.PubMedCrossRefGoogle Scholar
  234. 234.
    Jefferson JW: Serum lithium levels and long-term diuretic use. JAMA 241:1134–1136, 1979.PubMedCrossRefGoogle Scholar
  235. 235.
    Shulka S, Godwin CD, Long LE, et al: Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 141:1604–1606, 1984.Google Scholar
  236. 236.
    Prakash R, Kelwala S, Ban TA: Neurotoxicity with combined administration of lithium with a neuroleptic. Compr Psychiatry 23:567–571, 1982.PubMedCrossRefGoogle Scholar
  237. 237.
    Perry PJ, Calloway RA, Cook B, et al: Theophylline precipitated alterations in lithium clearance. Acta Psychiatr Scand 69:528–537, 1984.PubMedCrossRefGoogle Scholar
  238. 238.
    Ballenger JC, Post RM: Carbamazepine in manic-depressive illness: A new treatment. Am J Psychiatry 137:782–790, 1980.PubMedGoogle Scholar
  239. 239.
    Stromgrew LS, Boller S: Carbamazepine in treatment and prophylaxis of manic-depressive disorder. Psychiatry Dev 4:349–367, 1985.Google Scholar
  240. 240.
    Hsu LK: Lithium-resistant adolescent mania. J Am Acad Child Psychiatry 25:280–283, 1986.PubMedCrossRefGoogle Scholar
  241. 241.
    Trimble MR: Anticonvulsants in children and adolescents. J Child Adolesc Psychopharmacol 1:107–124, 1990.PubMedCrossRefGoogle Scholar
  242. 242.
    Levy R, Pitlick WH: Carbamazepine: Interaction with other drugs, in Woodbury DM, Penry JD, Pippenger CD (eds): Antiepileptic Drugs. New York, Raven Press, 1982, pp 497–505.Google Scholar
  243. 243.
    Kafantaris V, Campbell M, Padron-Gayol MV, Small AM, Locascio JJ, Rosenberg CR: Carbamazepine in hospitalized aggressive conduct disorder children: An open pilot study. Psychopharmacol Bull 28:193–199, 1992.PubMedGoogle Scholar
  244. 244.
    Silva RR, Muñoz DM, Alpert M: Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: A meta-analysis. J Am Acad Child Adolesc Psychiatry 35:352–358, 1996.PubMedCrossRefGoogle Scholar
  245. 245.
    Forsythe I, Butler R, Berg I, McGuire R: Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 33:524–534, 1991.PubMedCrossRefGoogle Scholar
  246. 246.
    Livingston S, Pauli L, Berman W: Carbamazepine in epilepsy. Nine year follow-up with special emphasis on untoward reaction. Dis Nerv Syst 35:103–107, 1974.PubMedGoogle Scholar
  247. 247.
    Killam FM, Fromm CH: Carbamazepine in the treatment of neuralgia: Use and side effects. Arch Neurol 19:129–136, 1968.CrossRefGoogle Scholar
  248. 248.
    Salzman MB, Valderrama E, Sood SK: Carbamazepine and fatal eosinophilic myocarditis. N Engl J Med 336:878–879, 1997.PubMedCrossRefGoogle Scholar
  249. 249.
    Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV: Polycystic ovaries and hyperandrogen-ism in women taking valproate for epilepsy. N Engl J Med 329:1383–1388, 1993.PubMedCrossRefGoogle Scholar
  250. 250.
    Rall TW, Schleifer LS: Drugs effective in the therapy of the epilepsies, in Gilman AG, Rall TW, Nies AS, et al (eds): The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 436–462.Google Scholar
  251. 251.
    Calabrese J, Delucchi G: Spectrum of efficacy of valproate in 55 patients with rapidcycling bipolar disorder. Am J Psychiatry 47:431–434, 1990.Google Scholar
  252. 252.
    McElroy SL, Keck P, Pope HG: Sodium valproate: Its use in primary psychiatric disorders. J Clin Psychopharmacol 7:16–24, 1987.PubMedGoogle Scholar
  253. 253.
    Paptheodorou G, Kutcher SP: Divalproex sodium treatment in late adolescent and young adult acute mania. Psychopharmacol Bull 29:213–219, 1993.Google Scholar
  254. 254.
    West SA, Keck PE, McElroy SL, Strakowski SM, Minnery KL, McConville BJ, Sorter MT: Open trial of valproate in the treatment of adolescent mania. J Child Adolesc Psychopharmacol 4:263–267, 1994.CrossRefGoogle Scholar
  255. 255.
    West SA, Keck PE, McElroy SL: Oral loading doses in the valproate treatment of adolescents with mixed bipolar disorder. J Am Acad Child Adolesc Psychiatry 5:225–231, 1995.Google Scholar
  256. 256.
    Keck PE, McElroy SL, Tugrul KC, Bennett JA: Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 54:305–308, 1993.PubMedGoogle Scholar
  257. 257.
    Dreifuss FE, Santilli N, Langer DH, et al: Valproic acid hepatic fatalities: A retrospective review. Neurology 37:379–385, 1987.PubMedCrossRefGoogle Scholar
  258. 258.
    Pope H, McElroy S, Keck P, et al: Valproate in the treatment of acute mania. Arch Gen Psychiatry 48:62–68, 1991.PubMedCrossRefGoogle Scholar
  259. 259.
    Janicak PG, Bishes RA: Advances in the treatment of mania and other acute psychotic disorders. Psychiatr Ann 17:145–149, 1987.Google Scholar
  260. 260.
    Biederman J: The diagnosis and treatment of adolescent anxiety disorders. J Clin Psychiatry 51(suppl): 20–26, 1990.PubMedGoogle Scholar
  261. 261.
    Biederman J: Clonazepam in the treatment of prepubertal children with panic-like symptoms. J Clin Psychiatry 48:38–41, 1987.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • John O. Viesselman
    • 1
    • 2
  1. 1.Children’s ServicesVentura County Behavioral Health, and private practiceVenturaUSA
  2. 2.Consulting Child PsychiatristCasa Pacifica Residential Facility and Shelter CareCamarilloUSA

Personalised recommendations